2016 NCCN Guidelines |
No follow-up needed |
CT at 12 mo, if stable, no further follow-up |
CT at 6-12 mo, if stable, then repeat CT at 18-24 mo |
CT at 3, 9, and 24 mo, consider PET or biopsy |
|
CT at 12 mo, if stable, no further follow-up |
CT at 6-12 mo, if stable, repeat CT at 18-24 mo |
CT at 3-6 mo, if stable, repeat CT at 9-12 mo and 24 mo |
CT at 3, 9, and 24 mo, consider PET or biopsy |
2017 Fleischner Society Guidelines |
No routine follow-up |
No routine follow-up |
CT at 6-12 mo, if stable, then repeat CT at 18-24 mo |
Consider CT, PET, or tissue sampling at 3 mo |
|
Optional CT at 12 mo |
Optional CT at 12 mo |
CT at 6-12 mo then CT at 18-24 mo |
Consider CT, PET or tissue sampling at 3 mo |
2013 ACCP Guidelines |
No follow-up needed |
CT at 12 mo |
CT at 6-12 mo, if stable, then repeat CT at 18-24 mo |
CT at 3, 9, and 24 mo, consider PET or biopsy |
|
No follow-up needed |
CT at 6-12 mo, if stable, repeat CT at 18-24 mo |
CT at 3-6 mo, if stable, repeat CT at 9-12 mo and 24 mo |
CT at 3, 9, and 24 mo, consider PET or biopsy |
2016 Clinical practice consensus guidelines for Asia |
Annual CT surveillance |
CT at 12 mo and then annual CT surveillance |
CT at 6-12 mo, if stable, then repeat CT at 18-24 mo and then annual CT surveillance |
CT at 3-6, 9-12, and 18-24 mo, if the nodule sclear growth then surgical biopsy |
|
Patient discussion |
CT at 6-12 mo, if stable, then repeat CT at 18-24 mo and then annual CT surveillance |
CT at 3, 6, and 12 mo then annual CT surveillance |
PET scan if hypermetabolic,surgical biopsy, if surgical biopsy is positive, then surgical resection |